MaxCyte (MXCT) AI Stock Analysis

• Market Cap: $233.90M
• Dividend Yield: N/A
• Average Volume (3M): 1.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: -14.48%
• EPS Growth: -12.34%
• Country: US
• Employees: 114
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): -0.10
• Shares Outstanding: 106,318,535
• 10 Day Avg. Volume: 949,223
• 30 Day Avg. Volume: 1,040,674
• PEG Ratio: 0.58
• Price to Book (P/B): 1.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.89
• Price Target Upside: 210.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 50 Neutral
• Price Target: $2.00 ▼(-9.91%Downside)

MaxCyte's financial challenges and valuation concerns weigh heavily on the stock's score. However, strong shareholder support, strategic plans, and a solid cash position provide a basis for potential recovery, especially if operational efficiencies improve and macroeconomic conditions stabilize.

Positive Factors

Earnings

MXCT delivers Q1 beat, driven by its milestone segment, and reaffirms its 2025 guide.

Financial Performance

MXCT held $175M of cash and holds no debt, indicating a strong balance sheet.

Product Development

Acquiring SeQure Dx is the first step beyond electroporation & new product launches in FY25 should continue this trend (and drive upside to organic growth).

Negative Factors

Customer Behavior

Biopharma customers have become more hesitant to make capital purchases of its systems, and this trend intensified.

Market Pressure

Shares are down 34% year-to-date reflecting broader market pressure on longer-duration assets, macro uncertainty, and its possible impact on MaxCyte’s customers.

Revenue Guidance

The 2025 revenue guide was lower than expected, particularly for core organic growth.

MaxCyte Business Overview & Revenue Model

Company Description

MaxCyte, Inc. (NASDAQ: MXCT) is a leading cell-engineering company that specializes in the development and commercialization of innovative cell-based therapies. The company operates primarily in the biotechnology sector, focusing on enabling the engineering of cells for research and commercial use through its proprietary flow electroporation technology. This technology facilitates the introduction of a wide variety of molecules into cells, which is crucial for gene editing, cell therapy, and drug development applications. MaxCyte's core products include its ExPERT platform, which is designed to support the rapid, scalable, and cost-effective development of cellular therapies.

How the Company Makes Money

MaxCyte generates revenue primarily through the sale and licensing of its ExPERT flow electroporation platform and related technologies. The company's revenue streams include product sales, which involve selling its electroporation instruments and disposable processing assemblies, and licensing agreements with biotechnology and pharmaceutical companies that utilize its technology for cell therapy and gene editing applications. Additionally, MaxCyte benefits from strategic partnerships and collaborations with major industry players, which often involve upfront payments, milestone payments, and royalties on commercialized products created with its technology. These partnerships not only provide financial gains but also enhance the company's market presence and technological advancements.

MaxCyte Financial Statement Overview

Summary

MaxCyte faces significant financial challenges, with persistent losses and negative cash flows. The company maintains a strong equity position and low leverage, but its inability to generate positive net income and cash flow raises concerns about sustainability. Improvements in operational efficiency and revenue growth are essential.

Income Statement

MaxCyte's income statement reveals a challenging financial situation. The company has consistently reported negative EBIT and net income over the years, indicating ongoing operational losses. The revenue growth has been inconsistent, with a decline in the most recent year. Gross profit margins remain high, suggesting cost management at the gross level is effective, but this does not translate into profitability due to high operational expenses.

Balance Sheet

The balance sheet shows a strong equity base with a high equity ratio, reflecting low leverage. The debt-to-equity ratio is favorable, indicating the company is not heavily reliant on debt. However, the return on equity is negative due to recurring net losses, which is a concern for shareholders.

Cash Flow

Cash flow analysis highlights a negative operating and free cash flow, which has been a consistent trend. The operating cash flow to net income ratio is unfavorable, indicating inefficiencies in converting net income into cash. An increase in financing cash flow shows reliance on external funding to support operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.63M	41.29M	44.26M	33.89M	26.17M
Gross Profit	31.53M	36.55M	39.16M	30.25M	23.40M
EBITDA	-46.41M	-44.13M	-20.87M	-16.76M	-9.94M
Net Income	-41.05M	-37.92M	-19.78M	-20.13M	-12.64M
Balance Sheet
Total Assets	239.47M	268.27M	286.65M	284.12M	51.78M
Cash, Cash Equivalents and Short-Term Investments	154.48M	168.29M	227.34M	255.04M	34.76M
Total Debt	18.03M	18.74M	16.09M	5.68M	6.97M
Total Liabilities	33.22M	36.11M	32.69M	21.22M	18.55M
Stockholders Equity	206.25M	232.17M	253.97M	262.90M	33.23M
Cash Flow
Free Cash Flow	-29.26M	-25.39M	-33.26M	-14.51M	-10.85M
Operating Cash Flow	-27.61M	-21.69M	-14.78M	-10.68M	-8.78M
Investing Cash Flow	6.93M	54.98M	-24.82M	-195.01M	-16.58M
Financing Cash Flow	2.06M	2.14M	2.89M	234.72M	28.90M

MaxCyte Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MXCT, the sentiment is Negative. The current price of 2.22 is above the 20-day moving average (MA) of 2.20, below the 50-day MA of 2.30, and below the 200-day MA of 3.35, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.28 is Neutral, neither overbought nor oversold. The STOCH value of 65.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MXCT.

MaxCyte Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TCMD	70 Outperform	$231.55M	15.04	8.12%	―	5.96%	-43.83%
CVRX	57 Neutral	$178.08M	―	-76.01%	―	25.62%	11.86%
RCEL	55 Neutral	$150.68M	―	-407.50%	―	32.24%	-66.93%
SNWV	55 Neutral	$298.04M	―	0.65%	―	61.50%	34.99%
Sector *	52 Neutral	$7.51B	0.24	-62.67%	2.30%	16.09%	0.95%
MXCT	50 Neutral	$233.90M	―	-19.62%	―	-14.48%	-12.34%
LUNG	45 Neutral	$116.75M	―	-60.68%	―	19.84%	5.77%

MaxCyte Corporate Events

MaxCyte Cancels AIM Market Trading for Common Stock

On June 25, 2025, MaxCyte, Inc. announced its decision to cancel the trading of its common stock on the AIM market of the London Stock Exchange, effective June 26, 2025. This move will not affect the company’s shares listed on the Nasdaq Global Select Market, where they will continue to trade under the ticker symbol MXCT.

The most recent analyst rating on (MXCT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on MaxCyte stock, see the MXCT Stock Forecast page.

MaxCyte Shareholders Approve Equity Plan Amendment

At the 2025 annual meeting held on June 18, MaxCyte‘s stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the authorized shares by 2,950,000. Additionally, all five proposals presented, including the election of directors and the ratification of CohnReznick LLP as the accounting firm, were approved, indicating strong shareholder support for the company’s strategic decisions.

The most recent analyst rating on (MXCT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on MaxCyte stock, see the MXCT Stock Forecast page.

MaxCyte Reports Q1 2025 Financial Results Amid Revenue Dip

On May 7, 2025, MaxCyte announced its financial results for the first quarter of 2025, showing a total revenue of $10.4 million, an 8% decrease from the previous year. The company reported core business revenue growth of 1% and a decline in Strategic Platform License (SPL) Program-related revenue. Despite a net loss of $10.3 million, MaxCyte remains confident in its growth prospects for 2025, driven by disciplined operational focus and strategic investments. The integration of SeQure Dx is progressing well, promising long-term opportunities in safety assessment services.